AUTHOR INDEX

(P = Proceedings, S = Supplement)

A farewell to Alasdair: 453
AARNOUTSE, R.E., DROSTE, J.A.H., VAN OOSTERHOUT, J.J.G., KOOPMANS, P.P., POPESCU, M., REISS, P., HEKSTER, Y.A. & BURGER, D.M. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers: 115
AFSHARI, R. *see* BATEMAN, D.N.
AHMED, M.S.-E. *see* HAMDY, S.I.
AIEMSA-ARD, J. *see* KUKONGVIRIYAPAN, V.
ALFIREVIC, A., STALFORD, A.C., VILAR, F.J., WILKINS, E.D G.L., PARK, B.K. & PIRMOHAMED, M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity: 158
ANDERSON, S.D. *see* LEE, D.K.C.
ANTILA, S. *see* JONSSON, E.N.
ARÉVALO-LORIDO, J.C., CARRETERO-GÓMEZ, J., BUREO-DACAL, J.C., MONTERO-LEAL, C. & BUREO-DACAL, P. Antiepileptic drug hypersensitivity syndrome in a patient treated with valproate: 415
ARLANDER, E., SJÖVALL, J., SÖRSTAD, J., NORSTEN-HÖÖG, C. & GUSTAFSSON, L.L. Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability: 14
ARONSON, J.K. Features of this month's *Journal*: 223
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BABER, N.S. & BEGG, E.J. The *British Journal of Clinical Pharmacology* Editors' Report for 2002: 329
ARTHURS, G.J. *see* HANNA, M.H.
ASGHAR, A. *see* WANG, Z.
ASTOBIETA, A. *see* JAUREGIZAR, N.
AVORN, J. *see* MANTEL-TEEUWISSE, A.K.

BABER, N. Complementary medicines, clinical pharmacology and therapeutics: 225
BABER, N.S. *see* ARONSON, J.K.
BACK, D.J. & KHOO, S.H. The role of clinical pharmacology in optimizing antiretroviral therapy: 473
BALIT, C.R. *see* ISBISTER, G.K.
BALKENHOL, N. *see* SCHWAHN, B.C.
BARNES, J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality: 226
BARNES J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety: 331
BARR, J. *see* KOZER, E.
BARRETT, J.H. *see* SACHSE, C.
BARZILAY, B. *see* KOZER, E.
BATEMAN, D.N., GOOD, A.M., AFSHARI, R. & KELLY, C.A. Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland: 596
BATHEN, J. *see* SLORDAL, L.
BAUER, S., STÖRMER, E., JOHNE, A., KRÜGER, H., BUDDE, K., NEUMAYER, H.-H., ROOTS, I. & MAI, I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients: 203
BAYERLE-EDER, M. *see* LANGENBERGER, H.
BEGG, E.J. *see* ARONSON, J.K.
BELL, A. *see* LOKE, Y.K.
BENNETT, K. *see* WILLIAMS, D.
BERKOVITCH, M. *see* KOZER, E.
BERTILSSON, L. *see* DALÉN, P.
BHAMBRA, U. *see* SACHSE, C.
BIEMOND, I. *see* KAMERLING, I.M.C.
BIOLLAZ, J. *see* NYÉKI, Á.
BIRKETT, D.J. *see* SORENSEN, L.B.
BJORNSSON, G.A., HAANÆS, H.R. & SKOGLUND, L.A. A randomized, double-blind crossover trial of paracetamol 1000 mg four times daily *vs* ibuprofen 600 mg: effect on swelling and other postoperative events after third molar surgery: 405
BLACK, C., KAYE, J.A. & JICK, H. MMR vaccine and idiopathic thrombocytopaenic purpura: 107
BLESCH, K.S. *see* GIESCHKE, R.
BOISSEL, J.-P. *see* HULOT, J.-S.
BOOBIS, A.R. *see* SACHSE, C.
BOOTH, A.C. *see* MORGAN, J.D.
BORN, J. *see* OLTMANNS, K.M.
BROCKMÖLLER, J. *see* KIRCHHEINER, J.
BROSEN, K. *see* JUSTESEN, U.S.
BÜSCHEL, B. *see* SCHWARZ, U.I.
BUCLIN, T. *see* NYÉKI, Á.
BUDDE, K. *see* BAUER, S.
BUDDE, K., NEUMAYER, H.-H., FRITSCHE, L., SULOWICZ, W., STOMPÓR, T. & ECKLAND, D. The pharmacokinetics of pioglitazone in patients with impaired renal function: 368
BUGGY, D. *see* HANNA, M.H.
BULKOWSTEIN, M. *see* KOZER, E.
BUREO-DACAL, J.C. *see* ARÉVALO-LORIDO, J.C.
BUREO-DACAL, P. *see* ARÉVALO-LORIDO, J.C.
BURGER, D.M. *see* AARNOUTSE, R.E.
BURGER, H.-U. *see* GIESCHKE, R.
BURGGRAAF, J. *see* KAMERLING, I.M.C.

CALVO, R. *see* JAUREGIZAR, N.
CARRETERO-GÓMEZ, J. *see* ARÉVALO-LORIDO, J.C.
CHARLESWORTH, A. *see* HULOT, J.-S.
CHEN, G.-L. *see* ZHU, B.
CHEN, X.Y., ZHAO, L.M. & ZHONG, D.F. A novel metabolic pathway of morphine: formation of morphine glucosides in cancer patients: 570
CHEN, X.-P. *see* ZHU, B.
CHEN-LEVI, Z. *see* KOZER, E.
CHIN-DUSTING, J.P.F. *see* PARNELL, M.M.
CHOUDHRI, S. *see* GALLICANO, K.
CHOY, A.M.J. *see* HERMAN, R.B.
CHRYSTYN, H. *see* MORGAN, J.D.
CHUA, C. *see* LEE, H.S.
CLARKE, C. *see* ROLAN, P.
COHEN, A.F. *see* DE VISSER, S.J.
COHEN, A.F. *see* KAMERLING, I.M.C.
COHEN, A.F. *see* KEMME, M.J.B.
COOPER, K.J., MARTIN, P.D., DANE, A.L., WARWICK, M.J., RAZA, A. & SCHNECK, D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects: 94
CORNET, F. *see* DE VISSER, S.J.
CORVOL, J.-C. *see* HULOT, J.-S.
COWAN, L.M. *see* CURRIE, G.P.
CUCHERAT, M. *see* HULOT, J.-S.
CURRIE, G.P. *see* LEE, D.K.C.
CURRIE, G.P., LEE, D.K.C., DEMPSEY, O.J., FOWLER, S.J., COWAN, L.M. & LIPWORTH, B.J. A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics: 609

DAHL, M.-L. *see* DALÉN, P.
DALÉN, P., DAHL, M.-L., ROH, H.-K., TYBRING, G., EICHELBAUM, M., WILKINSON, G.R. & BERTILSSON,

© 2003 Blackwell Science Ltd

AUTHOR INDEX

(P = Proceedings, S = Supplement)

A farewell to Alasdair: 453
AARNOUTSE, R.E., DROSTE, J.A.H., VAN OOSTERHOUT, J.J.G., KOOPMANS, P.P., POPESCU, M., REISS, P., HEKSTER, Y.A. & BURGER, D.M. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers: 115
AFSHARI, R. *see* BATEMAN, D.N.
AHMED, M.S.-E. *see* HAMDY, S.I.
AIEMSA-ARD, J. *see* KUKONGVIRIYAPAN, V.
ALFIREVIC, A., STALFORD, A.C., VILAR, F.J., WILKINS, E.D G.L., PARK, B.K. & PIRMOHAMED, M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity: 158
ANDERSON, S.D. *see* LEE, D.K.C.
ANTILA, S. *see* JONSSON, E.N.
ARÉVALO-LORIDO, J.C., CARRETERO-GÓMEZ, J., BUREO-DACAL, J.C., MONTERO-LEAL, C. & BUREO-DACAL, P. Antiepileptic drug hypersensitivity syndrome in a patient treated with valproate: 415
ARLANDER, E., SJÖVALL, J., SÖRSTAD, J., NORSTEN-HÖÖG, C. & GUSTAFSSON, L.L. Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability: 14
ARONSON, J.K. Features of this month's *Journal*: 223
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BABER, N.S. & BEGG, E.J. The *British Journal of Clinical Pharmacology* Editors' Report for 2002: 329
ARTHURS, G.J. *see* HANNA, M.H.
ASGHAR, A. *see* WANG, Z.
ASTOBIETA, A. *see* JAUREGIZAR, N.
AVORN, J. *see* MANTEL-TEEUWISSE, A.K.

BABER, N. Complementary medicines, clinical pharmacology and therapeutics: 225
BABER, N.S. *see* ARONSON, J.K.
BACK, D.J. & KHOO, S.H. The role of clinical pharmacology in optimizing antiretroviral therapy: 473
BALIT, C.R. *see* ISBISTER, G.K.
BALKENHOL, N. *see* SCHWAHN, B.C.
BARNES, J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality: 226
BARNES J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety: 331
BARR, J. *see* KOZER, E.
BARRETT, J.H. *see* SACHSE, C.
BARZILAY, B. *see* KOZER, E.
BATEMAN, D.N., GOOD, A.M., AFSHARI, R. & KELLY, C.A. Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland: 596
BATHEN, J. *see* SLORDAL, L.
BAUER, S., STÖRMER, E., JOHNE, A., KRÜGER, H., BUDDE, K., NEUMAYER, H.-H., ROOTS, I. & MAI, I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients: 203
BAYERLE-EDER, M. *see* LANGENBERGER, H.
BEGG, E.J. *see* ARONSON, J.K.
BELL, A. *see* LOKE, Y.K.
BENNETT, K. *see* WILLIAMS, D.
BERKOVITCH, M. *see* KOZER, E.
BERTILSSON, L. *see* DALÉN, P.
BHAMBRA, U. *see* SACHSE, C.
BIEMOND, I. *see* KAMERLING, I.M.C.
BIOLLAZ, J. *see* NYÉKI, Á.
BIRKETT, D.J. *see* SORENSEN, L.B.
BJORNSSON, G.A., HAANÆS, H.R. & SKOGLUND, L.A. A randomized, double-blind crossover trial of paracetamol 1000 mg four times daily *vs* ibuprofen 600 mg: effect on swelling and other postoperative events after third molar surgery: 405
BLACK, C., KAYE, J.A. & JICK, H. MMR vaccine and idiopathic thrombocytopaenic purpura: 107
BLESCH, K.S. *see* GIESCHKE, R.
BOISSEL, J.-P. *see* HULOT, J.-S.
BOOBIS, A.R. *see* SACHSE, C.
BOOTH, A.C. *see* MORGAN, J.D.
BORN, J. *see* OLTMANNS, K.M.
BROCKMÖLLER, J. *see* KIRCHHEINER, J.
BROSEN, K. *see* JUSTESEN, U.S.
BÜSCHEL, B. *see* SCHWARZ, U.I.
BUCLIN, T. *see* NYÉKI, Á.
BUDDE, K. *see* BAUER, S.
BUDDE, K., NEUMAYER, H.-H., FRITSCHE, L., SULOWICZ, W., STOMPÓR, T. & ECKLAND, D. The pharmacokinetics of pioglitazone in patients with impaired renal function: 368
BUGGY, D. *see* HANNA, M.H.
BULKOWSTEIN, M. *see* KOZER, E.
BUREO-DACAL, J.C. *see* ARÉVALO-LORIDO, J.C.
BUREO-DACAL, P. *see* ARÉVALO-LORIDO, J.C.
BURGER, D.M. *see* AARNOUTSE, R.E.
BURGER, H.-U. *see* GIESCHKE, R.
BURGGRAAF, J. *see* KAMERLING, I.M.C.

CALVO, R. *see* JAUREGIZAR, N.
CARRETERO-GÓMEZ, J. *see* ARÉVALO-LORIDO, J.C.
CHARLESWORTH, A. *see* HULOT, J.-S.
CHEN, G.-L. *see* ZHU, B.
CHEN, X.Y., ZHAO, L.M. & ZHONG, D.F. A novel metabolic pathway of morphine: formation of morphine glucosides in cancer patients: 570
CHEN, X.-P. *see* ZHU, B.
CHEN-LEVI, Z. *see* KOZER, E.
CHIN-DUSTING, J.P.F. *see* PARNELL, M.M.
CHOUDHRI, S. *see* GALLICANO, K.
CHOY, A.M.J. *see* HERMAN, R.B.
CHRYSTYN, H. *see* MORGAN, J.D.
CHUA, C. *see* LEE, H.S.
CLARKE, C. *see* ROLAN, P.
COHEN, A.F. *see* DE VISSER, S.J.
COHEN, A.F. *see* KAMERLING, I.M.C.
COHEN, A.F. *see* KEMME, M.J.B.
COOPER, K.J., MARTIN, P.D., DANE, A.L., WARWICK, M.J., RAZA, A. & SCHNECK, D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects: 94
CORNET, F. *see* DE VISSER, S.J.
CORVOL, J.-C. *see* HULOT, J.-S.
COWAN, L.M. *see* CURRIE, G.P.
CUCHERAT, M. *see* HULOT, J.-S.
CURRIE, G.P. *see* LEE, D.K.C.
CURRIE, G.P., LEE, D.K.C., DEMPSEY, O.J., FOWLER, S.J., COWAN, L.M. & LIPWORTH, B.J. A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics: 609

DAHL, M.-L. *see* DALÉN, P.
DALÉN, P., DAHL, M.-L., ROH, H.-K., TYBRING, G., EICHELBAUM, M., WILKINSON, G.R. & BERTILSSON,

© 2003 Blackwell Science Ltd

L. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to *CYP2D6* genotypes, and comparison with Caucasians: 630
DALEY-YATES, P. *see* SINGH, S.D.
DALHOFF, K. *see* SCHMIDT, L.E.
DALY, A.K. *see* KING, B.P.
DANE, A.L. *see* COOPER, K.J.
DARBYSHIRE, J. Clinical trials of antiretroviral drugs: the role of the MRC AIDS Therapeutic Trials Committee (ATTC) and the MRC Clinical Trials Unit (CTU): 469
DAVIS, K.R. *see* DHINDSA, P.
DAWSON, A. *see* ISBISTER, G.K.
DAWSON, A.H. *see* ISBISTER, G.K.
DE BOER, A. *see* MANTEL-TEEUWISSE, A.K.
DE JONG, J.C.E., VAN DEN BERG, P.B., TOBI, H. & DE JONG-VAN DEN BERG, L.T.W. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects: 591
DE JONG-VAN DEN BERG, L.T.W. *see* DE JONG, J.C.E.
DE MARTIN, S. *see* ORLANDO, R.
DE VISSER, S.J., VAN DER POST, J.P., DE WAAL, P.P., CORNET, F., COHEN, A.F. & VAN GERVEN, J.M.A. Biomarkers for the effects of benzodiazepines in healthy volunteers: 39
DE WAAL, P.P. *see* DE VISSER, S.J.
DECOSTERD, L.A. *see* NYÉKI, Á.
DEININGER, E. *see* OLTMANNS, K.M.
DEMPSEY, O.J. *see* CURRIE, G.P.
DERRY, S. *see* LOKE, Y.K.
DESAI, M., LI, L., DESTA, Z., MALIK, M. & FLOCKHART, D. Variability of heart rate correction methods for the QT interval: 511
DESTA, Z. *see* DESAI, M.
DHINDSA, P., DAVIS, K.R. & DONNELLY, R. Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study: 616
DITTRICH, P. *see* TOMASELLI, F.
DOMINIAK, P. *see* OLTMANNS, K.M.
DONNELLY, R. *see* DHINDSA, P.
DOWNES, F. *see* ISBISTER, G.K.
DREWE, J. *see* VRTIC, F.
DROSTE, J.A.H. *see* AARNOUTSE, R.E.

ECKLAND, D. *see* BUDDE, K.
EICHELBAUM, M. Progress in clinical pharmacology over the last 20 years: 458
EICHELBAUM, M. *see* DALÉN, P.
EL-ENANY, M. *see* HAMDY, S.I.
ELLIOTT, K.M. *see* HANNA, M.H.
ELUNG-JENSEN, T., HEISTERBERG, J., KAMPER, A.-L., SONNE, J. & STRANDGAARD, S. Blood pressure response to conventional and low-dose enalapril in chronic renal failure: 139
ENDO, N. *see* HAMDY, S.I.
EVANS, S. *see* KOZER, E.

FAN, L. *see* LEE, H.S.
FEELY, J. *see* WILLIAMS, D.
FEHM, H.L. *see* OLTMANNS, K.M.
FICHTL, B. *see* HEINEMANN, G.
FIRMIN, R.K. *see* MULLA, H.
FLOCKHART, D. *see* DESAI, M.
FLOYD, A. *see* JEPSEN, P.
FOSTER, B. *see* GALLICANO, K.
FOWLER, S.J. *see* CURRIE, G.P.
FRANCILLARD, M. *see* FREY, N.
FREY, N., LAVEILLE, C., PARAIRE, M., FRANCILLARD, M., HOLFORD, N.H.G. & JOCHEMSEN, R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation: 147
FRITSCHE, L. *see* BUDDE, K.
FUJIMURA, A. *see* TSURUOKA, S.
FUJIMURA, M. *see* ISHIURA, Y.
FUJIMURA, M. *see* MYOU, S.

GALLICANO, K., FOSTER, B. & CHOUDHRI, S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers: 199
GARNER, R.C. *see* SACHSE, C.
GELBOIN, H.V. *see* SOARS, M.G.
GEORGE, B. *see* MORGAN, J.D.
GIESCHKE, R., BURGER, H.-U., REIGNER, B., BLESCH, K.S. & STEIMER, J.-L. Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients: 252
GOH, B.C. *see* LEE, H.S.
GOOD, A.M. *see* BATEMAN, D.N.
GOODERHAM, N.J. *see* SACHSE, C.
GORSKI, J.C. *see* WANG, Z.
GREENBERG, R. *see* KOZER, E.
GRGURINOVICH, N. *see* SORENSEN, L.B.
GUSTAFSSON, L.L. *see* ARLANDER, E.

HAANÆS, H.R. *see* BJORNSSON, G.A.
HAEFELI, W.E. *see* VRTIC, F.
HAFNER, D. *see* SCHWAHN, B.C.
HAGGART, K. *see* LEE, D.K.C.
HALL, S.D. *see* WANG, Z.
HAMDY, S.I., HIRATSUKA, M., NARAHARA, K., ENDO, N., EL-ENANY, M., MOURSI, N., AHMED, M.S.-E. & MIZUGAKI, M. Genotyping of four genetic polymorphisms in the *CYP1A2* gene in the Egyptian population: 321
HAMDY, S.I., HIRATSUKA, M., NARAHARA, K., ENDO, N., EL-ENANY, M., MOURSI, N., AHMED, M.S.-E. & MIZUGAKI, M. Genotype and allele frequencies of *TPMT*, *NAT2*, *GST*, *SULT1A1* and *MDR-1* in the Egyptian population: 560
HAMPTON, J. *see* HULOT, J.-S.
HANNA, M.H., ELLIOTT, K.M., STUART-TAYLOR, M.E., ROBERTS, D.R., BUGGY, D. & ARTHURS, G.J. Comparative study of analgesic efficacy and morphine-sparing effect of intramuscular dexketoprofen trometamol with ketoprofen or placebo after major orthopaedic surgery: 126
HARRIS, N.D. *see* ROBINSON, R.T.C.E.
HASHIMOTO, T. *see* MYOU, S.
HEINEMANN, G., FICHTL, B. & VOGT, W. Pharmacokinetics of vanadium in humans after intravenous administration of a vanadium containing albumin solution: 241
HEINZERLING, H. *see* KAMERLING, I.M.C.
HEISTERBERG, J. *see* ELUNG-JENSEN, T.
HEKSTER, Y.A. *see* AARNOUTSE, R.E.
HELLER, S.R. *see* ROBINSON, R.T.C.E.
HERMAN, R.B., JESUDASON, P.J., MUSTAFA, A.M., HUSAIN, R., CHOY, A.M.J. & LANG, C.C. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans: 134
HIRATSUKA, M. *see* HAMDY, S.I.
HIROSE, T. *see* MYOU, S.
HIROSE, Y. *see* TSUBOTA, A.
HOHLFELD, T. *see* SCHWAHN, B.C.
HOLFORD, N.H.G. *see* FREY, N.
HOUGHTON, N. *see* SINGH, S.D.
HUANG, S.-L. *see* ZHU, B.
HULOT, J.-S., CUCHERAT, M., CHARLESWORTH, A., VAN VELDHUISEN, D.J., CORVOL, J.-C., MALLET, A., BOISSEL, J.-P., HAMPTON, J. & LECHAT, P. Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods: 299
HUSAIN, R. *see* HERMAN, R.B.
HUTT, A.J. *see* TAN, S.C.

IGA, T. *see* ISHIGURO, A.
IRELAND, R.H. *see* ROBINSON, R.T.C.E.
ISBISTER, G.K., BALIT, C.R., WHYTE, I.M. & DAWSON, A. Valproate overdose: a comparative cohort study of self poisonings: 398
ISBISTER, G.K., WHYTE, I.M., DOWNES, F., DAWSON, A.H. & MCGETTIGAN, P. Concomitant

overdosing of other drugs in patients with paracetamol poisoning: 325
ISHIGURO, A., KUBOTA, T., SASAKI, H., YAMADA, Y. & IGA, T. Common mutant alleles of *CYP2D6* causing the defect of CYP2D6 enzyme activity in a Japanese population: 414
ISHIURA, Y. *see* MYOU, S.
ISHIURA, Y., FUJIMURA, M., YAMAMORI, C., NOBATA, K., MYOU, S., KURASHIMA, K., MICHISHITA, Y. & TAKEGOSHI, T. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients: 504
IZUMI, N. *see* TSUBOTA, A.

JACKSON, S.H.D. *see* TAN, S.C.
JAMAL, S.K. *see* LANG, C.C.
JAUREGIZAR, N., WALD, J.A., ASTOBIETA, A., SASIAIN, J.M.R., LUKAS, J.C. & CALVO, R. Population pharmacokinetics of netilmicin in short-term prophylactic treatment: 552
JEPSEN, P., SKRIVER, M.V., FLOYD, A., LIPWORTH, L., SCHONHEYDER, H.C. & SORENSEN, H.T. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark: 216
JESUDASON, P.J. *see* HERMAN, R.B.
JICK, H. *see* BLACK, C.
JICK, S.S. *see* YANG, C.-C.
JOCHEMSEN, R. *see* FREY, N.
JOHNE, A. *see* BAUER, S.
JONES, R. *see* KAMERLING, I.M.C.
JONSSON, E.N., ANTILA, S., MCFADYEN, L., LEHTONEN, L. & KARLSSON, M.O. Population pharmacokinetics of levosimendan in patients with congestive heart failure: 544
JUSTESEN, U.S., KLITGAARD, N.A., BROSEN, K. & PEDERSEN, C. Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers: 100

KAMERLING, I.M.C., BURGGRAAF, J., VAN HAARST, A.D., OPPENHUIZEN-DUINKER, M.F., SCHOEMAKER, H.C., BIEMOND, I., JONES, R., HEINZERLING, H., COHEN, A.F. & MASCLEE, A.A.M. The effect of motilin on the rectum in healthy volunteers: 538
KAMIO, Y. *see* MYOU, S.
KAMPER, A.-L. *see* ELUNG-JENSEN, T.
KANEKO, S. *see* YASUI-FURUKORI, N.
KARLSSON, M.O. *see* JONSSON, E.N.
KAYE, D.M. *see* PARNELL, M.M.
KAYE, J.A. *see* BLACK, C.
KELLY, C.A. *see* BATEMAN, D.N.
KEMME, M.J.B., VD POST, J.P., SCHOEMAKER, R.C., STRAUB, M., COHEN, A.F. & VAN GERVEN, J.M.A. Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension: 518
KERN, W. *see* OLTMANNS, K.M.
KHOO, S.H. *see* BACK, D.J.
KHOO, Y.M. *see* LEE, H.S.
KING, B.P., LEATHART, J.B.S., MUTCH, E., WILLIAMS, F.M. & DALY, A.K. CYP3A5 phenotype-genotype correlations in a British population: 625
KIRBY, S.M. *see* SINGH, S.D.
KIRCH, W. *see* SCHWARZ, U.I.
KIRCHHEINER, J., MEINEKE, I., STEINBACH, N., MEISEL, C., ROOTS, I. & BROCKMÖLLER, J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans: 51
KITA, T. *see* MYOU, S.
KLITGAARD, N.A. *see* JUSTESEN, U.S.
KLUNGEL, O.H. *see* MANTEL-TEEUWISSE, A.K.
KNUTSON, L. *see* TANNERGREN, C.
KNUTSON, T. *see* TANNERGREN, C.
KONDO, T. *see* YASUI-FURUKORI, N.
KOOPMANS, P.P. *see* AARNOUTSE, R.E.
KOZER, E., EVANS, S., BARR, J., GREENBERG, R., SORIANO, I., BULKOWSTEIN, M., PETROV, I., CHEN-LEVI, Z., BARZILAY, B. & BERKOVITCH, M. Glutathione, glutathione-dependent enzymes and antioxidant status in erythrocytes from children treated with high-dose paracetamol: 234
KRÄHENBÜHL, S. *see* VRTIC, F.
KRAUSZ, K.W. *see* SOARS, M.G.
KROMHOUT, D. *see* MANTEL-TEEUWISSE, A.K.
KRÜGER, H. *see* BAUER, S.
KUBOTA, T. *see* ISHIGURO, A.
KUKONGVIRIYAPAN, V., PRAWAN, A., TASSANEYAKUL, W., AIEMSA-ARD, J. & WARASIHA, B. Arylamine *N*-acetyltransferase-2 genotypes in the Thai population: 278
KUMADA, H. *see* TSUBOTA, A.
KURASHIMA, K. *see* ISHIURA, Y.

LANG, C.C. *see* HERMAN, R.B.
LANG, C.C., JAMAL, S.K., MOHAMED, Z., MUSTAFA, M.R., MUSTAFA, A.M. & LEE, T.C. Evidence of an interaction between nifedipine and nafcillin in humans: 588
LANGENBERGER, H., SCHALLER, G., PLEINER, J., MITTERMAYER, F., BAYERLE-EDER, M. & WOLZT, M. C-peptide has no effect on forearm blood flow during local hyperinsulinaemia in healthy humans: 526
LARYEA, M.D. *see* SCHWAHN, B.C.
LAVEILLE, C. *see* FREY, N.
LAWSON, G. *see* MULLA, H.
LAYTON, D., RILEY, J., WILTON, L.V. & SHAKIR, S.A.W. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study: 166
LEATHART, J.B.S. *see* KING, B.P.
LECHAT, P. *see* HULOT, J.-S.
LEE, D.K.C. *see* CURRIE, G.P.
LEE, D.K.C., HAGGART, K., CURRIE, G.P., ANDERSON, S.D. & LIPWORTH, B.J. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis: 639
LEE, D.K.C., ROBB, F.M., SIMS, E.J., CURRIE, G.P., MCFARLANE, L.C. & LIPWORTH, B.J. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis: 310
LEE, H.S., GOH, B.C., FAN, L., KHOO, Y.M., WANG, L., LIM, R., ONG, A.B. & CHUA, C. Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients: 270
LEE, T.C. *see* LANG, C.C.
LEHTONEN, L. *see* JONSSON, E.N.
LENNARD, M.S. *see* ARONSON, J.K.
LENNERNÄS, H. *see* TANNERGREN, C.
LI, L. *see* DESAI, M.
LI, L. *see* WANG, Z.
LIGHTFOOT, T.J. *see* SACHSE, C.
LIM, R. *see* LEE, H.S.
LINDEMANS, A.D. *see* MANTEL-TEEUWISSE, A.K.
LINDHOLM, A. *see* ROBINSON, R.T.C.E.
LIPWORTH, B.J. *see* CURRIE, G.P.
LIPWORTH, B.J. *see* LEE, D.K.C.
LIPWORTH, B.J. *see* WILSON, A.M.
LIPWORTH, L. *see* JEPSEN, P.
LIU, Z.-Q. *see* ZHU, B.
LOKE, Y.K., BELL, A. & DERRY, S. Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient: 282
LUKAS, J.C. *see* JAUREGIZAR, N.

MAI, I. *see* BAUER, S.
MAIER, A. *see* TOMASELLI, F.
MALIK, M. *see* DESAI, M.
MALLET, A. *see* HULOT, J.-S.
MANTEL-TEEUWISSE, A.K., VERSCHUREN, W.M.M., KLUNGEL, O.H., KROMHOUT, D., LINDEMANS, A.D., AVORN, J., PORSIUS, A.J. & DE BOER, A.

Undertreatment of hypercholesterolaemia: a population-based study: 389
MARSH, K. Management of severe malaria: implications for research: 460
MARTIN, P.D. *see* COOPER, K.J.
MARX, E. *see* OLTMANNS, K.M.
MASCLEE, A.A.M. *see* KAMERLING, I.M.C.
MATZI, V. *see* TOMASELLI, F.
MAXWELL, S. & WALLEY, T. Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow's doctors: 496
MAYA, J.F. *see* WANG, Z.
MCFADYEN, L. *see* JONSSON, E.N.
MCFARLANE, L.C. *see* LEE, D.K.C.
MCGETTIGAN, P. *see* ISBISTER, G.K.
MEINEKE, I. & TÜRCK, D. Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients: 32
MEINEKE, I. *see* KIRCHHEINER, J.
MEISEL, C. *see* KIRCHHEINER, J.
MICHISHITA, Y. *see* ISHIURA, Y.
MIHARA, K. *see* YASUI-FURUKORI, N.
MINERS, J.O. *see* SORENSEN, L.B.
MITTERMAYER, F. *see* LANGENBERGER, H.
MIZUGAKI, M. *see* HAMDY, S.I.
MOHAMED, Z. *see* LANG, C.C.
MONTERO-LEAL, C. *see* ARÉVALO-LORIDO, J.C.
MORGAN, J.D., WRIGHT, D.J., CHRYSTYN, H., GEORGE, B., BOOTH, A.C. & SHOESMITH, D.J. Development, implementation and cost-effectiveness of a protocol for review of combination diuretic prescribing: 317
MOURSI, N. *see* HAMDY, S.I.
MULLA, H., NABI, F., NICHANI, S., LAWSON, G., FIRMIN, R.K. & UPTON, D.R. Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation: 23
MULLINS, F. *see* ROLAN, P.
MUSTAFA, A.M. *see* HERMAN, R.B.
MUSTAFA, A.M. *see* LANG, C.C.
MUTCH, E. *see* KING, B.P.
MYOU, S. *see* ISHIURA, Y.
MYOU, S., FUJIMURA, M., KAMIO, Y., HIROSE, T., KITA, T., TACHIBANA, H., ISHIURA, Y., WATANABE, K., HASHIMOTO, T. & NAKAO, S. Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients: 341

NABI, F. *see* MULLA, H.
NAKAO, S. *see* MYOU, S.
NARAHARA, K. *see* HAMDY, S.I.
NEUMAYER, H.-H. *see* BAUER, S.
NEUMAYER, H.-H. *see* BUDDE, K.
NICHANI, S. *see* MULLA, H.
NOBATA, K. *see* ISHIURA, Y.
NORSTEN-HÖÖG, C. *see* ARLANDER, E.
NUHSBAUMER, S. *see* TOMASELLI, F.
NYÉKI, Á., BUCLIN, T., BIOLLAZ, J. & DECOSTERD, L.A. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios: 62

OLTMANNS, K.M., DEININGER, E., WELLHOENER, P., SCHULTES, B., KERN, W., MARX, E., DOMINIAK, P., BORN, J., FEHM, H.L. & PETERS, A. Influence of captopril on symptomatic and hormonal responses to hypoglycaemia in humans: 347
ONG, A.B. *see* LEE, H.S.
OPPENHUIZEN-DUINKER, M.F. *see* KAMERLING, I.M.C.
ORLANDO, R., PICCOLI, P., DE MARTIN, S., PADRINI, R. & PALATINI, P. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function: 86
ORR, L.C. *see* WILSON, A.M.
OU-YANG, D.-S. *see* ZHU, B.

PADRINI, R. *see* ORLANDO, R.
PALATINI, P. *see* ORLANDO, R.
PARAIRE, M. *see* FREY, N.
PARK, B.K. *see* ALFIREVIC, A.
PARK, B.K. *see* PIRMOHAMED, M.
PARNELL, M.M., CHIN-DUSTING, J.P.F., STARR, J. & KAYE, D.M. Low-dose atorvastatin therapy does not augment endothelial function in active hypercholesterolaemic males: 212
PATEL, B.K. *see* TAN, S.C.
PEARSON, M. Training prescribers: past, present and future: 480
PEDERSEN, C. *see* JUSTESEN, U.S.
PETERS, A. *see* OLTMANNS, K.M.
PETROV, I. *see* KOZER, E.
PICCOLI, P. *see* ORLANDO, R.
PINTER, H. *see* TOMASELLI, F.
PINTER, J. *see* TOMASELLI, F.
PIRMOHAMED, M. & PARK, B.K. Adverse drug reactions: back to the future: 486
PIRMOHAMED, M. *see* ALFIREVIC, A.
PLEINER, J. *see* LANGENBERGER, H.
POPESCU, M. *see* AARNOUTSE, R.E.
PORSIUS, A.J. *see* MANTEL-TEEUWISSE, A.K.
PRAWAN, A. *see* KUKONGVIRIYAPAN, V.

Proceedings of the British Pharmacological Society Clinical Pharmacology Section 7–10 January 2003: 418
Professor Alasdair Muir Breckenridge CBE: 451

RAWLINS, M.D. Clinical pharmacology and therapeutics into the future: 483
RAWLINS, M.D. Making tomorrow's doctors better prescribers: 495
RAZA, A. *see* COOPER, K.J.
REIGNER, B. *see* GIESCHKE, R.
REISS, P. *see* AARNOUTSE, R.E.
RILEY, J. *see* LAYTON, D.
RILEY, R.J. *see* SOARS, M.G.
RITTER, J.M. *see* ARONSON, J.K.
ROBB, F. *see* WILSON, A.M.
ROBB, F.M. *see* LEE, D.K.C.
ROBERTS, D.R. *see* HANNA, M.H.
ROBINSON, R.T.C.E., HARRIS, N.D., IRELAND, R.H., LINDHOLM, A. & HELLER, S.R. Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization: 246
ROH, H.-K. *see* DALÉN, P.
ROLAN, P., TERPSTRA, I.J., CLARKE, C., MULLINS, F. & VISSER, J.N. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol: 314
ROOTS, I. *see* BAUER, S.
ROOTS, I. *see* KIRCHHEINER, J.

SORENSEN, H.T. *see* JEPSEN, P.
SORENSEN, L.B., SORENSEN, R.N., MINERS, J.O., SOMOGYI, A.A., GRGURINOVICH, N. & BIRKETT, D.J. Polymorphic hydroxylation of perhexiline *in vitro*: 635
SORENSEN, R.N. *see* SORENSEN, L.B.
SACHSE, C., BHAMBRA, U., SMITH, G., LIGHTFOOT, T.J., BARRETT, J.H., SCOLLAY, J., GARNER, R.C., BOOBIS, A.R., WOLF, C.R. & GOODERHAM, N.J. Polymorphisms in the cytochrome P450 CYP1A2 gene (*CYP1A2*) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism: 68
SAITO, T. *see* TSURUOKA, S.
SAMSTAD, S. *see* SLORDAL, L.
SASAKI, H. *see* ISHIGURO, A.
SASIAIN, J.M.R. *see* JAUREGIZAR, N.
SCHONHEYDER, H.C. *see* JEPSEN, P.
SCHALLER, G. *see* LANGENBERGER, H.
SCHMIDT, L.E. & DALHOFF, K. Concomitant overdosing of other drugs in patients with paracetamol poisoning: 326
SCHNECK, D.W. *see* COOPER, K.J.

SCHOEMAKER, H.C. *see* KAMERLING, I.M.C.
SCHOEMAKER, R.C. *see* KEMME, M.J.B.
SCHULTES, B. *see* OLTMANNS, K.M.
SCHWAHN, B.C., HAFNER, D., HOHLFELD, T., BALKENHOL, N., LARYEA, M.D. & WENDEL, U. Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria: 6
SCHWARZ, U.I., BÜSCHEL, B. & KIRCH, W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception: 112
SCOLLAY, J. *see* SACHSE, C.
SHAKIR, S.A.W. *see* LAYTON, D.
SHOESMITH, D.J. *see* MORGAN, J.D.
SIMS, E.J. *see* LEE, D.K.C.
SIMS, E.J. *see* WILSON, A.M.
SINGH, S.D., WHALE, C., HOUGHTON, N., DALEY-YATES, P., KIRBY, S.M. & WOODCOCK, A.A. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease: 375
SJÖVALL, J. *see* ARLANDER, E.
SKOGLUND, L.A. *see* BJORNSSON, G.A.
SKRIVER, M.V. *see* JEPSEN, P.
SLORDAL, L., SAMSTAD, S., BATHEN, J. & SPIGSET, O. A life-threatening interaction between lithium and celecoxib: 413
SMITH, G. *see* SACHSE, C.
SMOLLE, J. *see* TOMASELLI, F.
SMOLLE-JÜTTNER, F.M. *see* TOMASELLI, F.
SÖRSTAD, J. *see* ARLANDER, E.
SOARS, M.G., GELBOIN, H.V., KRAUSZ, K.W. & RILEY, R.J. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology: 175
SOMOGYI, A.A. *see* SORENSEN, L.B.
SONNE, J. *see* ELUNG-JENSEN, T.
SOOSAI, E. *see* VADDADI, K.S.
SORIANO, I. *see* KOZER, E.
SPIGSET, O. *see* SLORDAL, L.
STALFORD, A.C. *see* ALFIREVIC, A.
STARR, J. *see* PARNELL, M.M.
STEIMER, J-L. *see* GIESCHKE, R.
STEINBACH, N. *see* KIRCHHEINER, J.
STÖRMER, E. *see* BAUER, S.
STOMPÓR, T. *see* BUDDE, K.
STRANDGAARD, S. *see* ELUNG-JENSEN, T.
STRAUB, M. *see* KEMME, M.J.B.
STUART-TAYLOR, M.E. *see* HANNA, M.H.
SUGIMOTO, K. *see* TSURUOKA, S.
SULOWICZ, W. *see* BUDDE, K.
SWEATMAN, J. Good clinical practice: a nuisance, a help or a necessity for clinical pharmacology?: 1
SWIFT, C.G. *see* TAN, S.C.

TACHIBANA, H. *see* MYOU, S.
TAKAHATA, T. *see* YASUI-FURUKORI, N.
TAKEGOSHI, T. *see* ISHIURA, Y.
TAN, S.C., PATEL, B.K., JACKSON, S.H.D., SWIFT, C.G. & HUTT, A.J. Influence of age on the enantiomeric disposition of ibuprofen in healthy volunteers: 579
TAN, Z.-R. *see* ZHU, B.
TANNERGREN, C., KNUTSON, T., KNUTSON, L. & LENNERNÄS, H. The effect of ketoconazole on the *in vivo* intestinal permeability of fexofenadine using a regional perfusion technique: 182
TASSANEYAKUL, W. *see* KUKONGVIRIYAPAN, V.
TATEISHI, T. *see* YASUI-FURUKORI, N.
TERPSTRA, I.J. *see* ROLAN, P.
TESTA, M.A. *see* YANG, C.-C.
TOBI, H. *see* DE JONG, J.C.F.
TOMASELLI, F., DITTRICH, P., MAIER, A., WOLTSCHE, M., MATZI, V., PINTER, J., NUHSBAUMER, S., PINTER, H., SMOLLE, J. & SMOLLE-JÜTTNER, F.M. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by *in vivo* microdialysis: 620
TSUBOTA, A., HIROSE, Y., IZUMI, N. & KUMADA, H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection: 360
TSURUOKA, S., WAKAUMI, M., SUGIMOTO, K., SAITO, T. & FUJIMURA, A. Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study: 531
TÜRCK, D. *see* MEINEKE, I.
TYBRING, G. *see* DALÉN, P.

UPTON, D.R. *see* MULLA, H.

VADDADI, G. *see* VADDADI, K.S.
VADDADI, K.S., SOOSAI, E. & VADDADI, G. Low blood selenium concentrations in schizophrenic patients on clozapine: 307
VAN DEN BERG, P.B. *see* DE JONG, J.C.F.
VAN DER POST, J.P. *see* DE VISSER, S.J.
VAN GERVEN, J.M.A. *see* DE VISSER, S.J.
VAN GERVEN, J.M.A. *see* KEMME, M.J.B.
VAN HAARST, A.D. *see* KAMERLING, I.M.C.
VAN OOSTERHOUT, J.J.G. *see* AARNOUTSE, R.E.
VAN VELDHUISEN, D.J. *see* HULOT, J.-S.
VD POST, J.P. *see* KEMME, M.J.B.
VERSCHUREN, W.M.M. *see* MANTEL-TEEUWISSE, A.K.
VILAR, F.J. *see* ALFIREVIC, A.
VISSER, J.N. *see* ROLAN, P.
VOGT, W. *see* HEINEMANN, G.
VRTIC, F., HAEFELI, W.E., DREWE, J., KRÄHENBÜHL, S. & WENK, M. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug: 191

WAKAUMI, M. *see* TSURUOKA, S.
WALD, J.A. *see* JAUREGIZAR, N.
WALLEY, T. *see* MAXWELL, S.
WANG, L. *see* LEE, H.S.
WANG, L.-S. *see* ZHU, B.
WANG, Z., HALL, S.D., MAYA, J.F., LI, L., ASGHAR, A. & GORSKI, J.C. Diabetes mellitus increases the *in vivo* activity of cytochrome P450 2E1 in humans: 77
WARASIHA, B. *see* KUKONGVIRIYAPAN, V.
WARWICK, M.J. *see* COOPER, K.J.
WATANABE, K. *see* MYOU, S.
WELLHOENER, P. *see* OLTMANNS, K.M.
WENDEL, U. *see* SCHWAHN, B.C.
WENK, M. *see* VRTIC, F.
WHALE, C. *see* SINGH, S.D.
WHYTE, I.M. *see* ISBISTER, G.K.
WILKINS, ED G.L. *see* ALFIREVIC, A.
WILKINSON, G.R. *see* DALÉN, P.
WILLIAMS, D., BENNETT, K. & FEELY, J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care: 604
WILLIAMS, F.M. *see* KING, B.P.
WILSON, A.M., SIMS, E.J., ORR, L.C., ROBB, F. & LIPWORTH, B.J. An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge: 354
WILTON, L.V. *see* LAYTON, D.
WINSTANLEY, P. The contribution of clinical pharmacology to antimalarial drug discovery and development: 464
WOLF, C.R. *see* SACHSE, C.
WOLTSCHE, M. *see* TOMASELLI, F.
WOLZT, M. *see* LANGENBERGER, H.
WOODCOCK, A.A. *see* SINGH, S.D.
WOODS, K.L. NHS R & D achievements and future challenges: 477
WRIGHT, D.J. *see* MORGAN, J.D.

YAMADA, Y. *see* ISHIGURO, A.
YAMAMORI, C. *see* ISHIURA, Y.

YANG, C.-C., JICK, S.S. & TESTA, M.A. Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation: 288

YASUI-FURUKORI, N., TAKAHATA, T., KONDO, T., MIHARA, K., KANEKO, S. & TATEISHI, T. Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam: 382

ZHAO, L.M. *see* CHEN, X.Y.

ZHONG, D.F. *see* CHEN, X.Y.

ZHOU, H.-H. *see* ZHU, B.

ZHU, B., LIU, Z.-Q., CHEN, G.-L., CHEN, X.-P., OU-YANG, D.-S., WANG, L.-S., HUANG, S.-L., TAN, Z.-R. & ZHOU, H.-H. The distribution and gender difference of CYP3A activity in Chinese subjects: 264

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings, S = Supplement)

5-FU, 253
AAMU, 62
acenocoumarol, 314
acetylation, 278
acoustic rhinometry, 354
adenosine monophosphate, 354
adrenal, 375
adverse drug reactions, 158
adverse effects, 166, 591
AFMU, 62
airway cough sensitivity, 504
albumin, 241
allergic rhinitis, 354, 639
aminophylline, 341
amoxicillin, 216
amprenavir, 100
analgesia, 126
antidepressants, 591
antilipaemic agents, 389
antioxidant status, 234
antipsychotics, 596
antiretroviral therapy, 100
arterial distensibility, 616
arylamine-*N*-acetyltransferase, 278
aspirin, 282
asthma, 341
asthma therapy, 609
awareness, 347

β-adrenoceptor antagonist, 134
barostat and healthy volunteers, 538
benefit, 282
benzodiazepines, 39
betaine, 6
bioavailability, 14, 182
biomarker, 39
Biopharmaceutics Classification System, 182
blood flow, 212
blood pressure, 139, 347
bronchial asthma, 504
bronchial hyper-responsiveness, 609
bronchodilatation, 341

caffeine, 62
caffeine metabolites, 191
caffeine test, 68
cancer and noncancer Asian patients, 270
capecitabine, 253
capsaicin, 504
carbamazepine, 398
carbocysteine, 504
cardiomyopathy, 307
cardiovascular event, 282
centrally acting artihypertensive, 518
chlorzoxazone, 77
chronic heart failure, 134
chronic hepatitis C, 360
chronic renal failure, 139
clinical pharmacology and therapeutics, 496
clinical protocol, 1
clinical trial directive, 1
clinical trials data monitoring committees, 299
clozapine, 307
cognition, 39
cohort study, 591
colorectal cancer, 253
combination diuretic, 317
combination therapy, 100
comorbidity, 288
complementary medicines, 226, 331
congestive heart failure, 544
Controlled clinical trials, 299
COPD, 375
cost-effectiveness, 317
covariate, 552
COX-1, 51
COX-2, 51
COX-2 selective inhibitors, 166
C-peptide, 526
curriculum, 496
cyclosporin A, 203
CYP1A2, 321
CYP1A2, 62, 68
CYP2C9, 51
CYP2D6, 630
CYP2E1, 77
CYP3A, 264, 270
CYP3A4, 94
CYP3A5, 625
CYPD2D6, 635
cytochrome P450 1A2, 68
cytochrome P450, 51, 588, 625, 630, 635

debrisoquine, 630
delavirdine, 100
desloratadine, 639
dexketoprofen, 126
diabetes, 77
diabetes mellitus, 347
diclofenac, 51
dietary supplements, 226, 331
disease progression, 147
dose proportionality, 14
dose–response relationship, 139
dosing time, 531
drug, 139
drug absorption, 182
drug interaction, 203, 314, 588
drug licensing, 596
drug regimen, 405
drug safety, 166
drug therapy, 389
drug–drug interaction, 182
drug-metabolizing enzymes, 560

education, 496
efficacy, 331
Egyptians, 321, 560
elderly, 579
electrothermal atomic absorption spectrometry (ETAAS), 241
enalapril, 139
enalaprilat, 139
endothelial function, 616
endothelium, 212
epidemiology, 216
erythromycin, 86
essential oils, 226, 331
ethics committees, 1
extracorporeal membrane oxygenation, 23

febrile children, 234
fexofenadine, 182
food effect, 382
forearm blood flow, 526

garlic supplements, 199
gastrointestinal drugs, 591
gastrointestinal haemorrhage, 282
GCP, 1
gender, 264, 604
gene polymorphism, 68
General Medical Council, 496
General Practice Research Database, 288
genetic polymorphism, 278
genotype 1b, 360
gliclazide, 147
gliclazide MR, 147
glucoside conjugate, 570
glucuronide conjugate, 570
glutathione changes, 234
glutathione-dependent enzymes, 234
good manufacturing practice, 1

half-life, 241
haloperidol, 511
harm analysis, 282
heart rate, 347
heart rate correction, 511
herbal medicines, 226, 331
high viral load, 360
histamine, 354
HIV, 158
HLM monoclonal antibody, 175
homocysteine, 6

© 2003 Blackwell Science Ltd

homocystinuria, 6
homoeopathic remedies, 226, 331
hormones, 347
human, 347
human insulin, 246
human liver, 625
human lung, 620
hydroxymethylglutaryl–CoA reductase inhibitors, 288
hypercholesterolaemia, 212, 389
hyperkalaemia, 317
hyperlipidaemia, 288
hypersensitivity, 158
hypertensive patients, 518
hypoglycaemia, 246
hypoglycaemic effect, 147
hypoglycaemic response, 347
hypokalaemia, 317

ibuprofen, 191, 405, 579
ICH GCP, 1
idiopathic thrombocytopaenic purpura, 107
in vitro, 635
in vivo, 620
in vivo extrapolation, 635
inhaled corticosteroids, 375
inspections, 1
insulin, 526, 77
insulin aspart, 246
interaction, 32
interetchnic differences, 630
interferon alpha 2b, 360
interim analysis, 299
intestinal permeability, 182
intranasal glucocorticoids, 310
intrinsic clearance, 175
ischaemic heart disease, 604

ketoconazole, 182, 94

laboratories, 1
legislation, 226
leukotriene receptor antagonist, 609
levosimendan, 544
lignocaine, 86
lipid-lowering drugs, 288
liquid chromatography–ion trap mass spectrometry, 570
liver disease, 86
long-acting β_2-adrenoceptor agonist, 609

malformations, 216
mannitol, 639
MDR-1, 560
medication review, 317
MEGX test, 86
meloxicam, 32
menstrual cycle, 264
metabolism, 14, 203, 635
microdialysis, 620
microvascular, 616
midazolam, 264, 270
mixture model, 147
MMR vaccine, 107
mometasone, 354
mometasone furoate, 310
montelukast, 639
morphine, 126, 570
motilin, 538
myocarditis, 307

N-acetyltransferase 2, 191
nafcillin, 588
nasal challenge, 354
nasal hyper-reactivity, 639
NAT2, 62, 158
NAT2, 278
nelfinavir, 115
netilmicin, 552
neutral endopeptidase, 504
nifedipine, 588
nitrates, 604
nitric oxide, 212
NONMEM, 147, 544
nonsteroidal anti-inflammatory, 126
nonsteroidal anti-inflammatory drug, 32
non-steroidal anti-inflammatory drugs, 591
noradrenaline, 134
nortriptyline, 630
NSAID, 51

olprinone, 341
once daily, 115
oral anticoagulants, 314
organic anion transport, 191
overdose, 398

pain, 405
paracetamol, 405
parenteral infusion therapy, 241
patient-controlled analgesia, 126
patients, 203
PCR assay, 625
perennial allergic rhinitis, 310
perhexiline, 635
perinatal mortality, 216
P-glycoprotein, 94, 182
pharmacist intervention, 317
pharmacoepidemiology, 596
pharmacogenetics, 321, 560, 625
pharmacokinetic and pharmacodynamic modelling, 253
pharmacokinetic interaction, 100, 199
pharmacokinetics, 6, 14, 86, 115, 203, 241, 360, 368, 375, 382, 579, 620
pharmacovigilance, 331
phase I, 39
phenotyping, 62, 191
phosphodiesterase 3 inhibitors, 341
pioglitazone, 368
piperacillin, 620
poisoning, 398, 596
poisons information, 596
polymorphism, 158, 635
population pharmacokinetic, 552
population pharmacokinetics, 23, 544
population PKPD modelling, 147
postoperative pain, 126
potassium-sparing diuretic, 317
pregnancy, 216
prescribing, 496
prescription-event monitoring, 166
prescriptions, 398
preterm delivery, 216
prostaglandin E_2, 51
protease inhibitors, 100

QT interval, 511
quality assurance, 1
quality, 226
quazepam, 382

randomized trial, 405
reaction phenotyping, 175
recombinant CYP, 175
rectal administration, 14
rectum, 538
regulation, 226
renal failure, 531
renal impairment, 368
renal osteodystrophy, 531
repeated paracetamol, 234
research governance framework, 1
Resuscitation Council, 1
reverse transcriptase inhibitors, 100
ribavirin, 360
risk factors, 389
ritonavir, 115, 199
rofecoxib, 166
ropivacaine, 14
rosuvastatin, 94

saccadic eye movement, 39
saccadic eye movements, 518
safety, 216, 331
schizophrenia, 307
selective serotonin reuptake inhibitors, 591
selenium, 307
sequential methods, 299
spontaneous abortion, 216
St John's wort, 203
stereoselectivity, 579
sulphamethoxazole, 158
sulphonylurea, 616
swelling, 405
symptoms, 347
systemic bioactivity, 310

tamsulosin, 314
target site, 620
tazobactam, 620
theophylline, 23
thioridazine, 596
third molar surgery, 405
thromboxane B_2, 51
time interval, 382
tolerability, 14
tolerance, 518
trial design, 299
triamcinolone acetonide, 310

triangular test, 299
Type 2 diabetes, 368

ultra trace metal analysis, 241
undergraduate, 496

validated computers, 1
valproate, 398
vanadium, 241
vasodilation, 526
ventricular repolarization, 246
vitamin D, 531
volunteers, 1

WinNonMix, 552

© 2003 Blackwell Science Ltd